A recent real-world study indicates that adults over the age of 55 who use Zepbound (tirzepatide) for weight management experience a significant reduction in overall healthcare expenses over time.
Eli Lilly and Co. (NYSE:LLY) announced that sustained use of the drug leads to fewer hospital admissions and emergency room visits for overweight or obese patients.
Meaningful Cost Savings Emerge Over Time
The study, published in Diabetes, Obesity and Metabolism, is the first to evaluate this specific age demographic, which includes individuals enrolled in the Medicare GLP-1 Bridge program.
Researchers utilized two distinct analytical methods to estimate financial differences, excluding the direct cost of the medication itself.
